AKERS BIOSCIENCES INC. overview

Akers Biosciences, Inc. (“Akers”) (Nasdaq: AKER) and MyMD Pharmaceuticals, Inc. (“MYMD”) today announced that at Akers’ special meeting of stockholders held on April 15, 2021, Akers obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Akers and MYMD. MYMD previously obtained a sufficient number of written consents from its stockholders to consummate the merger. Upon closing, the combined company will be named MyMD...

Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting”) to vote on the proposed business combination with MyMD Pharmaceuticals (“MyMD”). The meeting will be held on April 15, 2021 at 10:00 a.m., Eastern Time, and will be “virtual,” meaning that you can participate in the meeting online at www.virtualshareholdermeeting.com/AKER2021SM . In connection with the Meeting, Akers’ board of directors has fixed the close...

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company’s name. The Company has not scheduled any earnings calls. The Company is investigating how this error occurred and reserves all rights to pursue all appropriate remedies upon learning more about the cause...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Akers Biosciences, Inc. (NasdaqCM: AKER) with MyMD Pharmaceuticals, Inc., pursuant to which Akers shareholders will end up owning just 20% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Akers Biosciences, Inc. - AKER PR Newswire NEW YORK, Nov. 18, 2020 NEW YORK , Nov. 18, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Akers Biosciences, Inc. ("Akers" or the "Company") ( AKER ) relating to its proposed merger into MyMD Pharmaceuticals. Under the...

MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last week. The companies plan to hold a video conference for investors on Wednesday, November 18, 2020 at 4:15 p.m. ET to provide additional context on the integrated company, the clinical pipeline and drug development plan, and the commercial potential of the targeted indications. To participate in the briefing session, please click on the link below to...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Akers Biosciences, Inc. (NasdaqCM: AKER) with MyMD Pharmaceuticals, Inc., pursuant to which Akers shareholders will end up owning just 20% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction...

RM LAW Announces Investigation of Akers Biosciences, Inc. PR Newswire BERWYN, Pa., Nov. 17, 2020 BERWYN, Pa. , Nov. 17, 2020 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ: AKER) regarding possible breaches of fiduciary duties and other violations of law related to Akers' agreement to merge with MYMD Pharmaceuticals, Inc. ("MYMD"). If you own shares of Akers Biosciences and would like to...